According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a “virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings.” Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or condition. The differences between the small molecules and biologics includes the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex molecular structure. They are usually derived from living organisms, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.
Publisher’s analysts forecast the global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020.
For more information about this report: http://www.reportsweb.com/global-next-generation-biologics-market-2016-2020 .
Covered in this report
The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.
The market is divided into the following segments based on geography:
Publisher’s report, Global Next-generation Biologics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
-F. Hofmann-La Roche
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001497948/sample .
Other prominent vendors
-BrainStorm Cell Therapeutics
-Celyad (Cardio3 BioSciences)
-Harvard Apparatus Regenerative Technology
-Living Cell Technologies
-Shire Regenerative Medicine
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001497948/buying .